Ireland
--:--IST
Active, not recruiting Not applicable

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

NCT04301518 · tracked via the Priya Life Science USA tracker
Sponsor
Sera Prognostics, Inc
Phase
Not applicable
Started
2020-11-06
Last updated
2024-12-06

Condition(s) studied

Preterm LaborPreterm Birth

Investigational drug(s) / intervention(s)

Multimodal intervention strategy

Multimodal intervention strategy: * Once weekly nurse support * 200 mg/daily micronized progesterone as vaginal suppository * 81 mg/daily low dose aspirin * two transvaginal ultrasounds * cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation

Study summary

This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria 1. Subject is 18 years of age or older 2. Subject is willing and able to provide informed consent and comply with intervention if applicable 3. Subject gestational age is currently within 18 0/7 and 20 6/7 weeks using best estimated due date 4. This is a singleton intrauterine pregnancy 5. Subject has no signs and/or symptoms of preterm labor and has intact membranes 6. Subject has had a 2nd trimester anatomic ultrasound, including evaluation of cervical length, completed by the date of enrollment, but no earlier than 18 7. In the opinion of the Investigator, the subject's delivery data will be accessible within 20 business days from delivery, and neonatal data will be available for data collection purposes within 20 business days from discharge Exclusion Criteria: 1. Subject has had a prior spontaneous preterm delivery (gestational age at birth less than 37 0/7 weeks gestation) 2. Subject has cervical length less than 25 millimeters (mm) on 2nd trimester transvaginal ultrasound at time of enrollment 3. Subject has taken progesterone or progesterone-derivative medication after 13 6/7 weeks gestation 4. Singleton gestation reduced from an original multiple gestation via embryonic reduction or vanishing twin 5. There is a known major fetal anomaly or chromosomal/ genetic abnormality 6. Placenta accreta spectrum disorder (accreta/ increta/ percreta) 7. Placenta covers the internal os by more than 2.5 centimeters (cm) at time of 2nd trimester anatomic ultrasound (18 0/7 and 20 6/7 weeks gestation) 8. The subject has experienced vaginal bleeding after 13 6/7 weeks gestation 9. One or more of the following uterine risk factors are present: fibroids \> 5.0cm, uterine malformation, history of classical cesarean section, history of prior uterine surgery with trans-myometrial penetration (excludes low transverse cesarean section) 10. The subject has a planned cesarean section or induction of labor prior to 370/7 weeks gestation 11. The subject had a cerclage or pessary placed prior to enrollment window in the current pregnancy 12. The subject has received enoxaparin, heparin, heparin sodium or other low molecular weight heparin since last menstrual period 13. Subject has current diagnosis of polyhydramnios 14. Subject has known use of illicit drugs in the current pregnancy, including cocaine, methamphetamine, and/or opioid use disorder in the current pregnancy 15. Subject is allergic to aspirin or has experienced gastrointestinal bleeding associated with use 16. Subject is allergic to peanuts and/or peanut oil used in exogenous progesterone formulation 17. Subject is participating in any other interventional research studies during the current pregnancy 18. Subject has tested positive for COVID-19 via an FDA-authorized diagnostic test for SARS-CoV-2 within the ten days prior to PreTRM® sample collection 19. Subject has been evaluated for COVID-19 salient symptoms per the American College of Obstetrics and Gynecology/ Society for Maternal Fetal Medicine (ACOG/SMFM) "Outpatient Assessment and Management for Pregnant Women with Suspected or Confirmed Novel Coronavirus (COVID-19)" in an emergency room (ER) or hospital setting since the last menstrual period (LMP) date. 20. Subject has a chronic medical disease(s) which require intensive medical surveillance and may increase the risk of preterm delivery to include: * Lupus * Chronic lung diseases on oxygen replacement * Cardiac disease with high risk of maternal mortality, including Marfan syndrome with dilated aortic root and significant pulmonary hypertension * Neuromuscular diseases at risk for pulmonary insufficiency (e.g. myotonic dystrophy) * Renal failure on dialysis * Uncontrolled or poorly controlled hyperthyroidism

Primary outcome measure(s)

  • Neonatal morbidity/mortality — Through initial neonate discharge from hospital after birth for all neonates, assessed up to 180 days.
    Reduction in composite neonatal morbidity and mortality in the PTB Prevention arm versus the Control arm.
  • Length of neonatal hospital stay — Through initial neonate discharge from hospital after birth for all neonates, assessed up to 180 days.
    Reduction in length of neonatal hospital stay for admissions from time of birth up to initial neonatal hospital discharge home or neonatal death, whichever occurs first, in the PTB Prevention arm versus the Control arm.

Trial sites (18)

FacilityCityRegionStatus
UCSD San Diego California
Yale New Haven Connecticut
Delaware/Christiana Care Newark Delaware
Emerald Coast Panama City Florida
University of Kentucky Healthcare Lexington Kentucky
Ochsner New Orleans Louisiana
LSU Shreveport Louisiana
Boston Medical Center Boston Massachusetts
Beaumont Hospital Royal Oak Michigan
High Risk Pregnancy Center Las Vegas Nevada
Mt Sinai New York New York
Cleveland Clinic Cleveland Ohio
Ohio Health Columbus Ohio
UTMB Galveston Texas
University of Virginia Charlottesville Virginia
Inova Health Care Services Falls Church Virginia
VPFW Richmond Virginia
MCW Milwaukee Wisconsin
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04301518 on ClinicalTrials.gov ↗ ← All trials in the USA